No Data
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results
Marinus Pharmaceuticals Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Express News | D. Boral Capital Maintains Buy on Marinus Pharma, Maintains $3 Price Target
JMP Securities Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating
Hold Rating on Marinus Pharmaceuticals Amid Strategic Uncertainty and TRUST-TSC Study Setbacks
RBC Capital Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating, Cuts Target Price to $1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}